Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has begun an exploratory feasibility study assessing a selected delivery mechanism for its intranasal therapeutic drug SPC-15 in the treatment of post-traumatic stress syndrome (“PTSD”). The company is partnering with a developer and manufacturer of innovative drug-delivery systems and … Continue reading InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Begin Feasibility Study of Proprietary Novel Intranasal Formulation for PTSD